Clinical development of bivalirudin (Angiox®): rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes
- 22 February 2006
- journal article
- review article
- Published by Hindawi Limited in International Journal of Clinical Practice
- Vol. 60 (3), 344-350
- https://doi.org/10.1111/j.1368-5031.2005.00823.x
Abstract
As the pathophysiology of acute coronary syndromes (ACS) has been clarified in recent years, major advances have been made in the management of the disease. The magnitude of the thrombotic process triggered upon plaque disruption is modulated by different elements that determine plaque and blood thrombogenicity. Thrombin plays a pivotal role in ACS because of its extensive procoagulant and prothrombotic actions. Antithrombotic therapy and powerful antiplatelet therapies, in addition to early percutaneous coronary intervention (PCI), have become central in the management of ACS. A number of options for anticoagulation regimens are available. However, many agents currently used have significant limitations, recognition of which has led to the development, evaluation and clinical introduction of the class of thrombin‐specific anticoagulant agents. This paper will discuss the clinical development of the direct thrombin inhibitor bivalirudin as the core anticoagulant in the contemporary PCI setting and the implications for its use in ACS.Keywords
This publication has 37 references indexed in Scilit:
- Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical centerThe American Journal of Cardiology, 2005
- Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)The American Journal of Cardiology, 2005
- Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationaleAmerican Heart Journal, 2004
- Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)The American Journal of Cardiology, 2004
- Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialThe Lancet, 2001
- Molecular Basis for the Susceptibility of Fibrin-bound Thrombin to Inactivation by Heparin Cofactor II in the Presence of Dermatan Sulfate but Not HeparinJournal of Biological Chemistry, 2001
- Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trialThe Lancet, 1999
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Kinetic Mechanism for the Interaction of Hirulog with ThrombinBiochemistry, 1994
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992